Cell-mediated immune responses to MUC1 fusion protein coupled to mannan.
The immunotherapy of cancer requires the definition of a suitable target for and the induction of a CD8+ cytotoxic lymphocyte reaction. In breast cancer, particularly mucins (MUC1) of the variable number of tandem repeat sequence may be a suitable target, but there has been a problem in inducing a cytotoxic response. MUC1 peptides, conjugated to carriers (keyhole-limpet hemocyanin or diphtheria toxoid) induce a humoral response and give poor tumor protection in mice and there is little cellular immunity. However, when MUC1 fusion protein is conjugated to mannan under oxidizing conditions, a cellular immune response is induced, with significant tumor protection, cytotoxic T lymphocytes and little antibody. The procedure may also be useful for other antigens.
Apostolopoulos
V
V
Austin Research Institute, Heidelberg, Victoria, Australia.
Pietersz
G A
GA
McKenzie
I F
IF
D000595:Amino Acid Sequence; D000818:Animals; D005260:Female; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular / Q000276:immunology*; D008351:Mannans / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D018396:Mucin-1 / Q000276:immunology*; D009374:Neoplasms, Experimental / Q000517:prevention & control; D011993:Recombinant Fusion Proteins / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D008351:Mannans; D018396:Mucin-1; D011993:Recombinant Fusion Proteins